Table of Content

1. Key Insights

2. Executive Summary

3. Acromegaly Epidemiology Overview at a Glance
3.1. Epidemiology (%) Distribution of Acromegaly in 2017
3.2. Epidemiology (%) Distribution of Acromegaly in 2030

4. Acromegaly (ACM): Disease Overview
4.1. Introduction
4.2. Signs and Symptoms
4.3. Classification of Pituitary Adenomas
4.4. Clinical Manifestations of Acromegaly
4.5. Etiology
4.6. Pathophysiology
4.7. Genetic Bases of Acromegaly
4.8. Pathogenesis
4.9. Diagnosis
4.9.1. Diagnosis Guidelines
4.9.2. Endocrine Society Clinical Practice Guideline-United Kingdom
4.9.3. American Association of Clinical Endocrinologists (AACE) - USA

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Methodology
5.3. Total Prevalent Cases of Acromegaly in the 7MM
5.4. Total Diagnosed Cases of Acromegaly in the 7MM

6. United States Epidemiology
6.1. Total Prevalent Cases of Acromegaly in the United States
6.2. Diagnosed Cases of Acromegaly in the United States
6.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in the United States
6.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in the US

7. EU5 Epidemiology
7.1. Germany
7.1.1. Total Prevalent Cases of Acromegaly in Germany
7.1.2. Diagnosed Cases of Acromegaly in Germany
7.1.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in Germany
7.1.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in Germany
7.2. France
7.2.1. Total Prevalent Cases of Acromegaly in France
7.2.2. Diagnosed Cases of Acromegaly in France
7.2.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in France
7.2.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in France
7.3. Italy
7.3.1. Total Prevalent Cases of Acromegaly in Italy
7.3.2. Diagnosed Cases of Acromegaly in Italy
7.3.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in Italy
7.3.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in Italy
7.4. Spain
7.4.1. Total Prevalent Cases of Acromegaly in Spain
7.4.2. Diagnosed Cases of Acromegaly in Spain
7.4.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in Spain
7.4.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in Spain
7.5. United Kingdom
7.5.1. Total Prevalent Cases of Acromegaly in the United Kingdom
7.5.2. Diagnosed Cases of Acromegaly in the United Kingdom
7.5.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in the United Kingdom
7.5.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in the United Kingdom

8. Japan Epidemiology
8.1. Total Prevalent Cases of Acromegaly in Japan
8.2. Diagnosed Cases of Acromegaly in Japan
8.3. Origin-Based Diagnosed Prevalent Cases of Acromegaly in Japan
8.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan

9. Appendix
9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight



List of Figures


Figure 1 Change in facial features in Acromegaly
Figure 2 Clinical Manifestations of Acromegaly
Figure 3 Clinical Features of Acromegaly
Figure 4 Etiology of Acromegaly
Figure 5 Pathophysiology of Acromegaly
Figure 6 Molecular Pathogenesis of Acromegaly
Figure 7 Normal and disrupted the GHRH–GH–IGF1 axis and molecular targets for therapy
Figure 8 Diagnostic Algorithm of Acromegaly
Figure 9 Total Prevalent Cases of Acromegaly in the 7MM (2017–2030)
Figure 10 Total Diagnosed Cases of Acromegaly in the 7MM (2017–2030)
Figure 11 Total Prevalent Cases of Acromegaly in the US (2017–2030)
Figure 12 Diagnosed Cases of Acromegaly in the US (2017–2030)
Figure 13 Origin Specific Diagnosed Prevalent Cases of Acromegaly in the US (2017–2030)
Figure 14 Total Prevalent Cases of Acromegaly in Germany (2017–2030)
Figure 15 Diagnosed Cases of Acromegaly in Germany (2017–2030)
Figure 16 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Germany (2017–2030)
Figure 17 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Germany (2017–2030)
Figure 18 Total Prevalent Cases of Acromegaly in France (2017–2030)
Figure 19 Diagnosed Cases of Acromegaly in France (2017–2030)
Figure 20 Origin Specific Diagnosed Prevalent Cases of Acromegaly in France (2017–2030)
Figure 21 Diagnosed Cases of Acromegaly Based on Type of Adenomas in France (2017–2030)
Figure 22 Total Prevalent Cases of Acromegaly in Italy (2017–2030)
Figure 23 Diagnosed Cases of Acromegaly in Italy (2017–2030)
Figure 24 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Italy (2017–2030)
Figure 25 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Italy (2017–2030)
Figure 26 Total Prevalent Cases of Acromegaly in Spain (2017–2030)
Figure 27 Diagnosed Cases of Acromegaly in Spain (2017–2030)
Figure 28 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Spain (2017–2030)
Figure 29 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Spain (2017–2030)
Figure 30 Total Prevalent Cases of Acromegaly in the UK (2017–2030)
Figure 31 Diagnosed Cases of Acromegaly in the UK (2017–2030)
Figure 32 Origin Specific Diagnosed Prevalent Cases of Acromegaly in the UK (2017–2030)
Figure 33 Diagnosed Cases of Acromegaly Based on Type of Adenomas in the UK (2017–2030)
Figure 34 Total Prevalent Cases of Acromegaly in Japan (2017–2030)
Figure 35 Diagnosed Cases of Acromegaly in Japan (2017–2030)
Figure 36 Origin Based Diagnosed Prevalent Cases of Acromegaly in Japan (2017–2030)
Figure 37 Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan (2017–2030)


List of Tables


Table 1 Summary of Acromegaly, Epidemiology and Key Events (2017–2030)
Table 2 The 2017 WHO Pathological Classification of Pituitary adenomas
Table 3 Mutated genes associated with acromegaly/gigantism
Table 4 Genes that contribute to the molecular pathogenesis of GH-secreting adenomas
Table 5 Total Prevalent Cases of Acromegaly in the 7MM (2017–2030)
Table 6 Total Diagnosed Prevalent Cases of Acromegaly in the 7MM (2017–2030)
Table 7 Total Prevalent Cases of Acromegaly in the US (2017–2030)
Table 8 Diagnosed Cases of Acromegaly in the US (2017–2030)
Table 9 Origin Specific Diagnosed Prevalent Cases of Acromegaly in the US (2017–2030)
Table 10 Total Prevalent Cases of Acromegaly in Germany (2017–2030)
Table 11 Diagnosed Cases of Acromegaly in Germany (2017–2030)
Table 12 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Germany (2017–2030)
Table 13 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Germany (2017–2030)
Table 14 Total Prevalent Cases of Acromegaly in France (2017–2030)
Table 15 Diagnosed Cases of Acromegaly in France (2017–2030)
Table 16 Origin Specific Diagnosed Prevalent Cases of Acromegaly in France (2017–2030)
Table 17 Diagnosed Cases of Acromegaly Based on Type of Adenomas in France (2017–2030)
Table 18 Total Prevalent Cases of Acromegaly in Italy (2017–2030)
Table 19 Diagnosed Cases of Acromegaly in Italy (2017–2030)
Table 20 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Italy (2017–2030)
Table 21 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Italy (2017–2030)
Table 22 Total Prevalent Cases of Acromegaly in Spain (2017–2030)
Table 23 Diagnosed Cases of Acromegaly in Spain (2017–2030)
Table 24 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Spain (2017–2030)
Table 25 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Spain (2017–2030)
Table 26 Total Prevalent Cases of Acromegaly in the UK (2017–2030)
Table 27 Diagnosed Cases of Acromegaly in the UK (2017–2030)
Table 28 Origin Specific Diagnosed Prevalent Cases of Acromegaly in the UK (2017–2030)
Table 29 Diagnosed Cases of Acromegaly Based on Type of Adenomas in the UK (2017–2030)
Table 30 Total Prevalent Cases of Acromegaly in Japan (2017–2030)
Table 31 Diagnosed Cases of Acromegaly in Japan (2017–2030)
Table 32 Origin Based Diagnosed Prevalent Cases of Acromegaly in Japan (2017–2030)
Table 33 Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan (2017–2030)